Loading
The one second-line CAR-T trial that failed, a reminder that manufacturing time and trial design can erase a real effect.
BELINDA, trial NCT03570892 sponsored by Novartis and reported in 2021, was the one second-line CAR-T trial that failed, a reminder that manufacturing time and trial design can erase a real effect. It randomised 322 patients with early-relapsed or refractory aggressive B-cell lymphoma to tisagenlecleucel or salvage chemotherapy and transplant and found no difference in event-free survival, which the record attributes to a long vein-to-vein time of 52 days, permitted crossover chemotherapy before CAR-T and a strict week-twelve event definition. OnCo links it to lymphoma, CAR-T, the pairing of CAR-T before transplant at early relapse and the JULIET, TRANSFORM and ZUMA-7 papers, and it is contradicted by ZUMA-7 and TRANSFORM, which used faster products and no crossover. Whether tisagenlecleucel would have matched them under the same design is the question the trial cannot answer.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
330 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-free survival (median)primary | Tisagenlecleucel | 162 | 3 months | 1.07 (0.82 to 1.4) | - | link |
| Standard care | 160 | 3 months |
The reason second-line CAR-T is offered with axicabtagene ciloleucel or lisocabtagene maraleucel rather than tisagenlecleucel. The trial is also the strongest evidence in the field that the interval between apheresis and infusion, and what is given during it, is part of the treatment rather than logistics around it.
TRANSFORM confirmed ZUMA-7's conclusion with a different CD19 CAR-T and a more permissive design that allowed bridging chemotherapy, making the results closer to real-world practice. Liso-cel's low toxicity makes it attractive for older or frailer patients and for outpatient delivery. Together the two trials made CAR-T the standard second-line therapy for early-relapsing aggressive lymphoma.
ZUMA-7 rewrote second-line treatment for aggressive lymphoma: patients whose disease returns within a year of R-CHOP should be offered CAR-T rather than salvage chemotherapy and transplant. It is also one of the few cell-therapy trials to show an overall survival benefit despite crossover. Patients relapsing later than 12 months were not studied and transplant remains standard for them if chemosensitive.
JULIET, with ZUMA-1, showed that CAR-T could rescue a substantial minority of adults with chemotherapy-refractory lymphoma and that complete responders often stay in remission. The lower toxicity of a 4-1BB construct and the option of bridging therapy made it usable in a broader population. The high drop-out between enrolment and infusion remains a lesson about turnaround time.
Shares Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early, ZUMA-7, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, TRANSFORM, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, TRANSCEND NHL 001.
Shares JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma, JULIET, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy.
Shares Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET, Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma, ZUMA-7.
Shares JULIET, TRANSCEND NHL 001, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, CAR-T cell therapy.
Shares JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma, Lymphoma treatments that did not work: the negative trials worth knowing, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, JULIET.
Shares TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, Report the time from apheresis to infusion as a trial endpoint, not a logistics footnote, TRANSCEND NHL 001, The CAR-T pathway in lymphoma: referral, apheresis, bridging and the waiting.
Shares Transplant or CAR-T at second line in diffuse large B-cell lymphoma, JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma, TRANSFORM: liso-cel CAR-T versus salvage chemotherapy and transplant in early-relapsing large B-cell lymphoma, JULIET.